Desvenlafaxine

Clonazepam and Desvenlafaxine Extended-Release pairs an active SNRI metabolite with a long-acting benzodiazepine. Desvenlafaxine inhibits neuronal reuptake of both serotonin and norepinephrine to reverse core neurochemical deficits in depression, while clonazepam mitigates acute agitation, panic, and sleep disturbances during therapy induction. Indicated for major depressive disorder with prominent anxiety and severe somatic distress.

Clonazepam and Desvenlafaxine Extended-Release pairs an active SNRI metabolite with a long-acting benzodiazepine. Desvenlafaxine inhibits neuronal reuptake of both serotonin and norepinephrine to reverse core neurochemical deficits in depression, while clonazepam mitigates acute agitation, panic, and sleep disturbances during therapy induction. Indicated for major depressive disorder with prominent anxiety and severe somatic distress.

Venlafaxine is a bicyclic phenylethylamine serotonin and norepinephrine reuptake inhibitor (SNRI). At lower doses (< 150 mg/day), it acts predominantly as an SSRI; at higher doses, it significantly blocks norepinephrine reuptake, providing dual neurotransmitter elevation. Prolonged-release capsules provide uniform 24-hour plasma levels. Indicated for major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder.

Venlafaxine is a bicyclic phenylethylamine serotonin and norepinephrine reuptake inhibitor (SNRI). At lower doses (< 150 mg/day), it acts predominantly as an SSRI; at higher doses, it significantly blocks norepinephrine reuptake, providing dual neurotransmitter elevation. Prolonged-release capsules provide uniform 24-hour plasma levels. Indicated for major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder.